-
Something wrong with this record ?
Design, synthesis, and antiproliferative effect of 2,9-bis[4-(pyridinylalkylaminomethyl)phenyl]-1,10-phenanthroline derivatives on human leukemic cells by targeting G-quadruplex
J. Guillon, C. Denevault-Sabourin, E. Chevret, M. Brachet-Botineau, V. Milano, A. Guédin-Beaurepaire, S. Moreau, L. Ronga, S. Savrimoutou, S. Rubio, J. Ferrer, J. Lamarche, JL. Mergny, MC. Viaud-Massuard, M. Ranz, E. Largy, V. Gabelica, F. Rosu,...
Archiv der Pharmazie.
2021 ;
354 (8) :
e2000450.
[pub] 20210414
Language English Country Germany
Document type Journal Article
Persistent link
https://www.medvik.cz/link/bmc22003969
- MeSH
- Leukemia, Myeloid, Acute drug therapy pathology MeSH
- K562 Cells MeSH
- Phenanthrolines chemical synthesis chemistry pharmacology MeSH
- G-Quadruplexes drug effects MeSH
- HL-60 Cells MeSH
- Humans MeSH
- Ligands MeSH
- Cell Line, Tumor MeSH
- Antineoplastic Agents chemical synthesis chemistry pharmacology MeSH
- Drug Design MeSH
- Fluorescence Resonance Energy Transfer MeSH
- Telomerase metabolism MeSH
- U937 Cells MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Current multiagent chemotherapy regimens have improved the cure rate in acute leukemia patients, but they are highly toxic and poorly efficient in relapsed patients. To improve the treatment approaches, new specific molecules are needed. The G-quadruplexes (G4s), which are noncanonical nucleic acid structures found in specific guanine-rich DNA or RNA, are involved in many cellular events, including control of gene expression. G4s are considered as targets for the development of anticancer agents. Heterocyclic molecules are well known to target and stabilize G4 structures. Thus, a new series of 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives (1a-i) was designed, synthesized, and evaluated against five human myeloid leukemia cell lines (K562, KU812, MV4-11, HL60, and U937). Their ability to stabilize various oncogene promoter G4 structures (c-MYC, BCL-2, and K-RAS) as well as the telomeric G4 was also determined through the fluorescence resonance energy transfer melting assay and native mass spectrometry. In addition, the more bioactive ligands 1g-i were tested for telomerase activity in HuT78 and MV4-11 protein extracts.
IECB Université Bordeaux CNRS INSERM UMS 3033 US001 Pessac France
Institute of Biophysics Czech Academy of Sciences v v i Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003969
- 003
- CZ-PrNML
- 005
- 20220127145700.0
- 007
- ta
- 008
- 220113s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ardp.202000450 $2 doi
- 035 __
- $a (PubMed)33852185
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Guillon, Jean $u ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, UFR des Sciences Pharmaceutiques, Bordeaux, France
- 245 10
- $a Design, synthesis, and antiproliferative effect of 2,9-bis[4-(pyridinylalkylaminomethyl)phenyl]-1,10-phenanthroline derivatives on human leukemic cells by targeting G-quadruplex / $c J. Guillon, C. Denevault-Sabourin, E. Chevret, M. Brachet-Botineau, V. Milano, A. Guédin-Beaurepaire, S. Moreau, L. Ronga, S. Savrimoutou, S. Rubio, J. Ferrer, J. Lamarche, JL. Mergny, MC. Viaud-Massuard, M. Ranz, E. Largy, V. Gabelica, F. Rosu, F. Gouilleux, V. Desplat
- 520 9_
- $a Current multiagent chemotherapy regimens have improved the cure rate in acute leukemia patients, but they are highly toxic and poorly efficient in relapsed patients. To improve the treatment approaches, new specific molecules are needed. The G-quadruplexes (G4s), which are noncanonical nucleic acid structures found in specific guanine-rich DNA or RNA, are involved in many cellular events, including control of gene expression. G4s are considered as targets for the development of anticancer agents. Heterocyclic molecules are well known to target and stabilize G4 structures. Thus, a new series of 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives (1a-i) was designed, synthesized, and evaluated against five human myeloid leukemia cell lines (K562, KU812, MV4-11, HL60, and U937). Their ability to stabilize various oncogene promoter G4 structures (c-MYC, BCL-2, and K-RAS) as well as the telomeric G4 was also determined through the fluorescence resonance energy transfer melting assay and native mass spectrometry. In addition, the more bioactive ligands 1g-i were tested for telomerase activity in HuT78 and MV4-11 protein extracts.
- 650 _2
- $a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a rezonanční přenos fluorescenční energie $7 D031541
- 650 _2
- $a G-kvadruplexy $x účinky léků $7 D054856
- 650 _2
- $a HL-60 buňky $7 D018922
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a buňky K562 $7 D020014
- 650 _2
- $a akutní myeloidní leukemie $x farmakoterapie $x patologie $7 D015470
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a fenantroliny $x chemická syntéza $x chemie $x farmakologie $7 D010618
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a telomerasa $x metabolismus $7 D019098
- 650 _2
- $a U937 buňky $7 D020298
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Denevault-Sabourin, Caroline $u Groupe Innovation et Ciblage Cellulaire, UFR des Sciences Pharmaceutiques, Université Tours, EA GICC-ERL 7001 CNRS, Tours, France
- 700 1_
- $a Chevret, Edith $u Cutaneous Lymphoma Oncogenesis Team, Bordeaux Research in Translational Oncology (BaRITOn), Université Bordeaux, INSERM U1053, Bordeaux, France
- 700 1_
- $a Brachet-Botineau, Marie $u Groupe Innovation et Ciblage Cellulaire, UFR des Sciences Pharmaceutiques, Université Tours, EA GICC-ERL 7001 CNRS, Tours, France $u Service d'Hématologie Biologique, CHRU de Tours, Tours, France
- 700 1_
- $a Milano, Vittoria $u ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, UFR des Sciences Pharmaceutiques, Bordeaux, France
- 700 1_
- $a Guédin-Beaurepaire, Aurore $u ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, UFR des Sciences Pharmaceutiques, Bordeaux, France
- 700 1_
- $a Moreau, Stéphane $u ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, UFR des Sciences Pharmaceutiques, Bordeaux, France
- 700 1_
- $a Ronga, Luisa $u Institut des Sciences Analytiques et de Physico-Chimie pour l'Environnement et les Matériaux, Université de Pau et des Pays de l'Adour, E2S UPPA, CNRS UMR 5254, IPREM, Pau, France
- 700 1_
- $a Savrimoutou, Solène $u ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, UFR des Sciences Pharmaceutiques, Bordeaux, France
- 700 1_
- $a Rubio, Sandra $u ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, UFR des Sciences Pharmaceutiques, Bordeaux, France
- 700 1_
- $a Ferrer, Jacky $u Cutaneous Lymphoma Oncogenesis Team, Bordeaux Research in Translational Oncology (BaRITOn), Université Bordeaux, INSERM U1053, Bordeaux, France
- 700 1_
- $a Lamarche, Jeremy $u Institut des Sciences Analytiques et de Physico-Chimie pour l'Environnement et les Matériaux, Université de Pau et des Pays de l'Adour, E2S UPPA, CNRS UMR 5254, IPREM, Pau, France
- 700 1_
- $a Mergny, Jean-Louis $u ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, UFR des Sciences Pharmaceutiques, Bordeaux, France $u Institute of Biophysics, Czech Academy of Sciences, v.v.i., Brno, Czech Republic
- 700 1_
- $a Viaud-Massuard, Marie-Claude $u Groupe Innovation et Ciblage Cellulaire, UFR des Sciences Pharmaceutiques, Université Tours, EA GICC-ERL 7001 CNRS, Tours, France
- 700 1_
- $a Ranz, Matthieu $u ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, Institut Européen de Chimie et Biologie, Pessac, France
- 700 1_
- $a Largy, Eric $u ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, Institut Européen de Chimie et Biologie, Pessac, France
- 700 1_
- $a Gabelica, Valérie $u ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, Institut Européen de Chimie et Biologie, Pessac, France
- 700 1_
- $a Rosu, Frédéric $u IECB (Institut Européen de Chimie et Biologie), Université Bordeaux, CNRS, INSERM, UMS 3033 US001, Pessac, France
- 700 1_
- $a Gouilleux, Fabrice $u Service d'Hématologie Biologique, CHRU de Tours, Tours, France
- 700 1_
- $a Desplat, Vanessa $u Cellules souches hématopoïétiques normales et leucémiques, UFR des Sciences Pharmaceutiques, Université Bordeaux, INSERM, U1035, Bordeaux, France
- 773 0_
- $w MED00000507 $t Archiv der Pharmazie $x 1521-4184 $g Roč. 354, č. 8 (2021), s. e2000450
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33852185 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145656 $b ABA008
- 999 __
- $a ok $b bmc $g 1751431 $s 1155118
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 354 $c 8 $d e2000450 $e 20210414 $i 1521-4184 $m Archiv der Pharmazie $n Arch Pharm $x MED00000507
- LZP __
- $a Pubmed-20220113
